Aadi bioscience announces financial results for the second quarter 2023 and provides corporate update

Continued growth in total revenue on fyarro® with sales of $6.2 million for 2q 2023 on-track for interim analysis on 40 patients in precision1 trial before the end of 2023 expanding pipeline to include programs in endometrial cancer and neuroendocrine tumors (nets) conference call to be held today at 8:30 am est los angeles , aug. 9, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mtor pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023. "we are seeing continued growth in fyarro sales and are pleased with the positive feedback we are receiving from the treatment community," said scott giacobello, interim ceo and president and cfo of aadi.
AADI Ratings Summary
AADI Quant Ranking